18:16 , Nov 9, 2018 |  BC Week In Review  |  Clinical News

Early data for Enyo's HBV, NASH candidate tee up Phase II

Enyo Pharma S.A. (Lyon, France) said once-daily oral EYP001 for four weeks was well tolerated with no off-target effects or serious adverse events reported in a Phase Ib trial to treat chronic HBV infection. The...
02:27 , Nov 3, 2018 |  BioCentury  |  Product Development

New partners for NASH

Pharmas are loading up their NASH portfolios expecting that addressing the full disease spectrum will require combinations, though the field lacks the tools to sort the different mechanisms on offer strategically. Meanwhile, at least three...
20:14 , Oct 5, 2018 |  BC Week In Review  |  Financial News

New IPO filings include NGM, Arog, Gamida

Three biotechs filed late Sept. 28 to go public on NASDAQ, adding new companies to a 2018 class of IPOs that could surpass 2015's record for funds raised. The group includes NGM Biopharmaceuticals Inc. (South...
12:22 , Oct 1, 2018 |  BC Extra  |  Financial News

New IPO filings include NGM, Arog, Gamida

Three more biotechs filed late Friday to go public on NASDAQ, adding new companies to a 2018 class of IPOs that could surpass 2015's record for funds raised. The group includes NGM Biopharmaceuticals Inc. (South...
16:41 , Jun 8, 2018 |  BC Week In Review  |  Financial News

Metacrine raises $65M series C

Metacrine Inc. (San Diego, Calif.) raised $65 million on June 6 in an untranched series C round led by Venrock Healthcare. New investors Franklin Templeton Investments, Deerfield Management, Arrowmark Partners, Invus, Lilly Asia Ventures and...
15:22 , Jun 8, 2018 |  BC Week In Review  |  Financial News

Enyo aims for Phase II HBV, NASH trials with €40M round

Enyo Pharma S.A. (Lyon, France) raised €40 million ($46.8 million) in a series B round led by OrbiMed Advisors. New investors Andera Partners (formerly Edmond de Rothschild Investment Partners) and Bpifrance Large Venture also participated,...
19:48 , Jun 6, 2018 |  BC Extra  |  Financial News

Metacrine raises $65M series C

Metacrine Inc. (San Diego, Calif.) raised $65 million in an untranched series C round led by Venrock Healthcare. New investors Franklin Templeton Investments, Deerfield Management, Arrowmark Partners, Invus, Lilly Asia Ventures and Vivo Capital also...
14:09 , Jun 4, 2018 |  BC Extra  |  Financial News

Enyo aims for Phase II HBV, NASH trials with €40M round

Enyo Pharma S.A. (Lyon, France) raised €40 million ($46.8 million) in a series B round led by OrbiMed Advisors. New investors Andera Partners (formerly Edmond de Rothschild Investment Partners) and Bpifrance Large Venture also participated,...
19:49 , Apr 27, 2018 |  BC Week In Review  |  Clinical News

NGM reports Phase II data for NGM282 in primary sclerosing cholangitis

NGM Biopharmaceuticals Inc. (South San Francisco, Calif.) reported additional data from a Phase II trial in 62 primary sclerosing cholangitis (PSC) patients with elevated alkaline phosphatase levels showing that once-daily subcutaneous 3 mg NGM282 significantly...
19:32 , Apr 27, 2018 |  BC Week In Review  |  Clinical News

NGM's NGM282 meets in Phase II data for NASH

NGM Biopharmaceuticals Inc. (South San Francisco, Calif.) reported data from a single-blind Phase II trial in 19 non-alcoholic steatohepatitis (NASH) patients showing that once-daily subcutaneous 3 mg NGM282 met the primary endpoint of reducing absolute...